Interleukin-6-receptor inhibitors like Tocilizumab and Satralizumab, are now being considered as good options for treatment of NMO/NMOSD and potential therapeutic effects of Tocilizumab and Satralizumab have been investigated via clinical trials and have shown promising results in the treatment of active NMOSD case, however, summarized data is lacking [11]. This evidence concerns the gene IL6R and neuromyelitis optica.